Landry Christine S, Brock Guy, Scoggins Charles R, McMasters Kelly M, Martin Robert C G
Division of Surgical Oncology, Department of Surgery and James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY 40202, USA.
J Am Coll Surg. 2008 Dec;207(6):874-81. doi: 10.1016/j.jamcollsurg.2008.08.013.
Colon carcinoid remains an uncommon finding during screening endoscopy or operation, with little known about the longterm prognosis. The reason for this uncertainty is that no staging system exists to appropriately risk stratify or follow these patients for overall survival. We sought to investigate prognostic factors associated with colon carcinoid tumors and create a predictive staging system to accurately estimate prognosis.
A search of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database identified 15,983 patients with carcinoid tumors, with 2,459 from the colon, from 1973 to 2004. Patients were analyzed to various clinicopathologic factors and a tumor (T1, T2, T3), lymph node (N0, N1), and metastasis (M0, M1) staging system was created according to these parameters.
Of the 2,459 patients, 1,287 (52%) women and 1,172 (48%) men were identified, with a median age of 63 years (range, 12 to 96 years). Lymph node metastasis was found in 820 (48%), and distant metastatic disease was present in 522 (24%) patients. On multivariate analysis, age, size, depth of invasion, lymph node involvement, distant metastasis, and location were significant. Four stages were created to statistically significant prognostic factors: 13% into stage I, 32% into stage II, 12% into stage III, and 43% into stage IV. Five-year survival rates were 97%, 69%, 21%, and 17% for stages I through IV (p = 0.001).
The newly developed TNM staging system accurately discriminates prognosis for carcinoid tumors of the colon. Incorporation of this staging system into clinical practice will allow better study of outcomes and development of stage-specific treatment recommendations.
在筛查性内镜检查或手术中,结肠类癌仍然是一种罕见的发现,对其长期预后了解甚少。这种不确定性的原因是不存在一种分期系统来对这些患者进行适当的风险分层或跟踪其总体生存情况。我们试图研究与结肠类癌肿瘤相关的预后因素,并创建一个预测分期系统来准确估计预后。
对美国国立癌症研究所的监测、流行病学和最终结果(SEER)数据库进行检索,确定了1973年至2004年间15983例类癌肿瘤患者,其中2459例来自结肠。对患者进行了各种临床病理因素分析,并根据这些参数创建了肿瘤(T1、T2、T3)、淋巴结(N0、N1)和转移(M0、M1)分期系统。
在2459例患者中,确定有1287例(52%)为女性,1172例(48%)为男性,中位年龄为63岁(范围12至96岁)。820例(48%)发现有淋巴结转移,522例(24%)患者存在远处转移疾病。多因素分析显示,年龄、大小、浸润深度、淋巴结受累情况、远处转移和部位具有显著性。根据具有统计学意义的预后因素创建了四个分期:13%为I期,32%为II期,12%为III期,43%为IV期。I至IV期的五年生存率分别为97%、69%、21%和17%(p = 0.001)。
新开发的TNM分期系统能准确区分结肠类癌肿瘤的预后。将该分期系统纳入临床实践将有助于更好地研究预后并制定针对特定分期的治疗建议。